Skip to content
Screener

Guardant Health GH Q4 2025 Annual earnings

Reported February 19, 2026 · After market close

Revenue$281.3MBeat by $8.8M
EPS-$0.90Miss by $0.13
Revenue estimate$272.4M
EPS estimate-$0.77

Next report

Oct 28, 2026 (in 2 months)
Revenue estimate$350.1M
EPS estimate-$0.28

Financials

Q4 2025

Income statement

See full
Revenue$281.3M+39.4%
Gross profit$181.8M+46.3%
Operating income-$120.8M+4.1%
Net income-$128.5M-15.8%
EPS (diluted)-$1.00-11.1%

Balance sheet

See full
Cash & equivalents$489.4M-22.3%
Total debt$1.7B+28.0%
Total equity-$99.3M+28.9%
Total assets$2.0B+35.5%

Cash flow

See full
Operating cash flow-$26.4M+59.1%
CapEx$27.8M+47.5%
Free cash flow-$54.2M+35.0%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$13.27B+251%
Enterprise value$14.49B+223%
P/S13.5×+8.4×

Profitability

See full
Gross margin64.5%+3.7pp
Operating margin-44.5%-9.1pp
Net margin-42.4%-9.3pp
FCF margin-23.7%-6.3pp

Returns & leverage

See full
Current ratio4.8×+0.2×

Segments

By product

See full
Oncology$189.9M+30.4%
Biopharma and data$54.0M+9.1%
Screening$35.1M+752%
Licensing and other$2.2M-15.0%

By segment

See full
Reportable Segment$281.3M+39.4%

FAQ

When did Guardant Health report Q4 2025 earnings?
Guardant Health (GH) reported Q4 2025 earnings on February 19, 2026 after market close.
What were Guardant Health's Q4 2025 revenue and EPS?
Guardant Health reported revenue of $281.3M and eps of $-0.90 for Q4 2025.
Did Guardant Health beat estimates in Q4 2025?
Revenue beat the consensus estimate of $272.4M by $8.8M. EPS missed the consensus estimate of $-0.77 by $0.13.
How did Guardant Health's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 39.4% from $201.8M a year earlier and eps declined 45.2% from $-0.62.
Where can I find Guardant Health's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001576280-26-000012) and the 10-K periodic report (0001576280-26-000013) directly on SEC EDGAR. The filing index links above go to sec.gov.